Review



cd34-a700 antibody  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher cd34-a700 antibody
    Cd34 A700 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34-a700+antibody/cd34+antibody/pmc08633042-11-0-2
    Average 90 stars, based on 1 article reviews
    cd34-a700 antibody - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Glutamate transporter Slc1a3 mediates inter‐niche stem cell activation during skin growth
    Article Snippet: The following antibodies were used: CD34‐A700 (rat, 1:100; eBioscience #56‐0341‐82), CD49f (Integrin alpha 6)‐PE (rat, 1:1,000; eBioscience #12‐0495‐81), Sca1‐PerCP‐Cy5.5 (rat, 1:500; eBioscience #45‐5981).

    Article Title: TIFAB accelerates MLL-AF9−Induced acute myeloid leukemia through upregulation of HOXA9
    Article Snippet: CD34-A700 , eBioscience , #56-0341-82.



    Similar Products

    cd34-a700 antibody  (Thermo Fisher)
    90
    Thermo Fisher cd34-a700 antibody
    Cd34 A700 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34-a700+antibody/cd34+antibody/pmc08633042-11-0-2
    Average 90 stars, based on 1 article reviews
    cd34-a700 antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cd34 a700  (R&D Systems Hematology)
    93
    R&D Systems Hematology cd34 a700
    Phenotypic effect of ITPP treatment on tumor metabolism. a RT-PCR analysis revealing: downregulation of hypoxia/oxygen sensing genes and prometastasis genes; upregulation of genes implicated in endothelial cells maturation. Results are percent of non treated samples level ( n = 8 animals, five separate experiments; ** p = 0.001; *** p = 0.0001). b Reduction of the number of CXCR4 + <t>CD34</t> + CD45 − precursor cells among tumor cells upon ITPP treatment. Quantification by flow cytometry from separate tumor samples ( n = 10/group p < 0.001). c Flow cytometry quantitative analysis showing a dramatic decrease in the number of cells expressing hypoxia-, stress-, and metastasis- related markers in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; 5 separate experiments, ** p = 0.001; *** p = 0.0001). d Flow cytometry quantification analysis showing a dramatic decrease in the number of cells expressing markers of high energetic metabolism in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; five separate experiments; *** p = 0.0001)
    Cd34 A700, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34-a700+antibody/Rat+CD34+Antibody/pmc03695680-53-39-42
    Average 93 stars, based on 1 article reviews
    cd34 a700 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Phenotypic effect of ITPP treatment on tumor metabolism. a RT-PCR analysis revealing: downregulation of hypoxia/oxygen sensing genes and prometastasis genes; upregulation of genes implicated in endothelial cells maturation. Results are percent of non treated samples level ( n = 8 animals, five separate experiments; ** p = 0.001; *** p = 0.0001). b Reduction of the number of CXCR4 + CD34 + CD45 − precursor cells among tumor cells upon ITPP treatment. Quantification by flow cytometry from separate tumor samples ( n = 10/group p < 0.001). c Flow cytometry quantitative analysis showing a dramatic decrease in the number of cells expressing hypoxia-, stress-, and metastasis- related markers in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; 5 separate experiments, ** p = 0.001; *** p = 0.0001). d Flow cytometry quantification analysis showing a dramatic decrease in the number of cells expressing markers of high energetic metabolism in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; five separate experiments; *** p = 0.0001)

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Stable tumor vessel normalization with pO 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment

    doi: 10.1007/s00109-013-0992-6

    Figure Lengend Snippet: Phenotypic effect of ITPP treatment on tumor metabolism. a RT-PCR analysis revealing: downregulation of hypoxia/oxygen sensing genes and prometastasis genes; upregulation of genes implicated in endothelial cells maturation. Results are percent of non treated samples level ( n = 8 animals, five separate experiments; ** p = 0.001; *** p = 0.0001). b Reduction of the number of CXCR4 + CD34 + CD45 − precursor cells among tumor cells upon ITPP treatment. Quantification by flow cytometry from separate tumor samples ( n = 10/group p < 0.001). c Flow cytometry quantitative analysis showing a dramatic decrease in the number of cells expressing hypoxia-, stress-, and metastasis- related markers in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; 5 separate experiments, ** p = 0.001; *** p = 0.0001). d Flow cytometry quantification analysis showing a dramatic decrease in the number of cells expressing markers of high energetic metabolism in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; five separate experiments; *** p = 0.0001)

    Article Snippet: Labeled primary antibodies used were the following: antimouse-CD31-PE (rat Ig-G2a, eBioscience) or CD31-PerCP (rat IgG2a, R&D), -VEGF R1-PE (Rat IgG2b, R&D), -VEGF R2-PE (Rat IgG2a, R&D), -CXCR4-PE (Rat IgG2b, R&D), -CD45-PerCP (rat IgG2b, R&D) or CD45-PE-Cy7 (rat IgG2b, R&D), -CD34-A700 (rat IgG2a, R&D).

    Techniques: Reverse Transcription Polymerase Chain Reaction, Flow Cytometry, Expressing

    Effect of ITPP treatment on tumor hypoxia-induced resistance, stem cell selection, and enhancement of chemotherapeutic efficacy. a The P-glycoprotein immunostaining showing a reduced number of multidrug resistance positive tumor cells after ITPP treatment. Frozen sections of primary tumors from experiments described in Fig. were histochemically labeled (day 22, ITPP treatments as described in “ ” ( n = 8/group; five separate experiments). Scale bars = 50 μm. b Quantification by flow cytometry showing the reduction of cells positive for precursor and stem cell-associated markers (CD133, Oct3-4, ABCG-2) after ITPP treatment. CD133 + immunostaining corroborated the reduction visible on frozen section staining of primary tumors as in a . Scale bars = 50 μm. c Lung metastasis is suppressed by chemotherapeutic drugs (Paclitaxel and Cisplatin), when treatment is preceded by ITPP injection. Tumor cells are detected by their Lucifease activity in the lungs of animals from control, ITPP, CisPt plus Paclitaxel and combined treatments ITPP + drugs as described in “ .” Data are reported for day 22 ( n = 10/group; 5 experiments; ***; p = 0.001). d CD31 staining of endothelial cells ( green ) and eosin/hematoxylin staining obtained in primary tumor frozen sections from experiment described in c . Efficient tissue necrosis was obtained when chemotherapeutic treatment is preceded by ITPP injection as described in “ .” Scale bars = 50 μm

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Stable tumor vessel normalization with pO 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment

    doi: 10.1007/s00109-013-0992-6

    Figure Lengend Snippet: Effect of ITPP treatment on tumor hypoxia-induced resistance, stem cell selection, and enhancement of chemotherapeutic efficacy. a The P-glycoprotein immunostaining showing a reduced number of multidrug resistance positive tumor cells after ITPP treatment. Frozen sections of primary tumors from experiments described in Fig. were histochemically labeled (day 22, ITPP treatments as described in “ ” ( n = 8/group; five separate experiments). Scale bars = 50 μm. b Quantification by flow cytometry showing the reduction of cells positive for precursor and stem cell-associated markers (CD133, Oct3-4, ABCG-2) after ITPP treatment. CD133 + immunostaining corroborated the reduction visible on frozen section staining of primary tumors as in a . Scale bars = 50 μm. c Lung metastasis is suppressed by chemotherapeutic drugs (Paclitaxel and Cisplatin), when treatment is preceded by ITPP injection. Tumor cells are detected by their Lucifease activity in the lungs of animals from control, ITPP, CisPt plus Paclitaxel and combined treatments ITPP + drugs as described in “ .” Data are reported for day 22 ( n = 10/group; 5 experiments; ***; p = 0.001). d CD31 staining of endothelial cells ( green ) and eosin/hematoxylin staining obtained in primary tumor frozen sections from experiment described in c . Efficient tissue necrosis was obtained when chemotherapeutic treatment is preceded by ITPP injection as described in “ .” Scale bars = 50 μm

    Article Snippet: Labeled primary antibodies used were the following: antimouse-CD31-PE (rat Ig-G2a, eBioscience) or CD31-PerCP (rat IgG2a, R&D), -VEGF R1-PE (Rat IgG2b, R&D), -VEGF R2-PE (Rat IgG2a, R&D), -CXCR4-PE (Rat IgG2b, R&D), -CD45-PerCP (rat IgG2b, R&D) or CD45-PE-Cy7 (rat IgG2b, R&D), -CD34-A700 (rat IgG2a, R&D).

    Techniques: Selection, Immunostaining, Labeling, Flow Cytometry, Staining, Injection, Activity Assay, Control